therapies, investigational

Oral PD-L1 inhibitor GS-4224 selectively engages PD-L1 high cells and elicits pharmacodynamic responses in patients with advanced solid tumors
Jared M Odegard, Ahmed A Othman, Kai-Wen Lin, Adele Y Wang, Jonathan Nazareno, Oh Kyu Yoon, John Ling, Latesh Lad, P Rod Dunbar, Dung Thai, Edmond Ang, Nicholas Waldron, Sanjeev Deva

Journal for ImmunoTherapy of Cancer Apr 2024, 12 (4) e008547; DOI: 10.1136/jitc-2023-008547
Metastatic gastric cancer target lesion complete response with Claudin18.2-CAR T cells
Gregory P Botta, Joseph Chao, Hong Ma, Michael Hahn, Gloria Sierra, Jie Jia, Amanda Y Hendrix, Joy V Nolte Fong, Audrey Ween, Peter Vu, Aaron Miller, Michael Choi, Benjamin Heyman, Gregory A Daniels, Dan Kaufman, Catriona Jamieson, Zonghai Li, Ezra Cohen

Journal for ImmunoTherapy of Cancer Feb 2024, 12 (2) e007927; DOI: 10.1136/jitc-2023-007927
iRECIST and atypical patterns of response to immuno-oncology drugs
Jorge Luis Ramon-Patino, Sabine Schmid, Sally Lau, Lesley Seymour, Pierre-Olivier Gaudreau, Janice Juan Ning Li, Penelope Ann Bradbury, Emiliano Calvo

Journal for ImmunoTherapy of Cancer Jun 2022, 10 (6) e004849; DOI: 10.1136/jitc-2022-004849
Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumab
Geoffrey Alan Watson, Enrique Sanz-Garcia, Wen-Jiang Zhang, Zhihui Amy Liu, SY Cindy Yang, Ben Wang, Shaofeng Liu, Shawn Kubli, Hal Berman, Thomas Pfister, Sofia Genta, Anna Spreafico, Aaron R Hansen, Philippe L Bedard, Stephanie Lheureux, Albiruni Abdul Razak, Dave Cescon, Marcus O Butler, Wei Xu, Tak W Mak, Lillian L Siu, Eric Chen

Journal for ImmunoTherapy of Cancer Jun 2022, 10 (6) e004378; DOI: 10.1136/jitc-2021-004378
Regression of EGFR positive established solid tumors in mice with the conditionally active T cell engager TAK-186
Danielle E Dettling, Eilene Kwok, Lucy Quach, Aakash Datt, Jeremiah D Degenhardt, Anand Panchal, Pui Seto, Jessica L Krakow, Russell Wall, Brian J Hillier, Ying Zhu, Maia Vinogradova, Robert B DuBridge, Chad May

Journal for ImmunoTherapy of Cancer Jun 2022, 10 (6) e004336; DOI: 10.1136/jitc-2021-004336
Intratumoral administration of the immunologic adjuvant AS01_B in combination with autologous CD1c (BDCA-1)⁺/CD141 (BDCA-3)⁺ myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma
Jens Tijtgat, Xenia Geeraerts, Anais Boisson, Latoya Stevens, Manon Vounckx, Iris Dirven, Julia Katharina Schwarze, Steven Raeymaeckers, Ramses Forsyth, Ivan Van Riet, Sandra Tuyaerts, Karen Willard-Gallo, Bart Neyns

Journal for ImmunoTherapy of Cancer Jan 2024, 12 (1) e008148; DOI: 10.1136/jitc-2023-008148
Safety and efficacy of the tumor-selective adenovirus enadenotucirev, in combination with nivolumab, in patients with advanced/metastatic epithelial cancer: a phase I clinical trial (SPICE)
Marwan Fakih, Wael Harb, Daruka Mahadevan, Hani Babiker, Jordan Berlin, Tom Lillie, David Krige, Jo Carter, Chris Cox, Minesh Patel, Lola Parfitt, Mark Powell, Lee Rosen

Journal for ImmunoTherapy of Cancer Apr 2023, 11 (4) e006561; DOI: 10.1136/jitc-2022-006561
Durable response of anaplastic thyroid carcinoma to FS118, a bispecific LAG-3/PD-L1 antibody, after checkpoint inhibitor progression: a case report
Maxwell J Kroloff, Josefin-Beate Holz, Omer Stern, Christopher J Shepherd, Michelle Morrow, Louis Kayitalire, Deborah J Wong

Journal for ImmunoTherapy of Cancer Oct 2022, 10 (10) e005225; DOI: 10.1136/jitc-2022-005225
First communication on the efficacy of combined ¹⁷⁷Lutetium-PSMA with immunotherapy outside prostate cancer
Antonia Digklia, Sarah Boughdad, Krisztian Homicsko, Clarisse Dromain, Mounir Trimech, Ana Dolcan, Solange Peters, John Prior, Niklaus Schaefer

Journal for ImmunoTherapy of Cancer Oct 2022, 10 (10) e005383; DOI: 10.1136/jitc-2022-005383
First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors
Omid Hamid, Alberto A Chiappori, John A Thompson, Toshihiko Doi, Siwen Hu-Lieskovan, Ferry A L M Eskens, Willeke Ros, Adi Diab, Jean-Philippe Spano, Naiyer A Rizvi, Jeffrey S Wasser, Eric Angevin, Patrick A Ott, Alison Forgie, Wenjing Yang, Cen Guo, Jeffrey Chou, Anthony B El-Khoueiry

Journal for ImmunoTherapy of Cancer Oct 2022, 10 (10) e005471; DOI: 10.1136/jitc-2022-005471

Main menu

therapies, investigational

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

therapies, investigational

Pages